1 Preeclampsia prediction with maternal and paternal polygenic risk scores: the TMM 2 **BirThree Cohort Study** 3 Hisashi OHSETO, MD,¹ Mami ISHIKURO, PhD,^{1,2} Taku OBARA, PhD,^{1,2,3} Akira NARITA, 4 PhD,^{1,2} Ippei TAKAHASHI, MMSc,¹ Genki SHINODA, MS,^{1,2} Aoi NODA, PhD^{1,2} Keiko 5 MURAKAMI, MPH, PhD,² Masatsugu ORUI, MD, PhD,^{1,2} Noriyuki IWAMA, MD, PhD,^{1,2,3} 6 Masahiro KIKUYA, MD, PhD,^{2,4} Hirohito METOKI, MD, PhD,^{2,5} Junichi SUGAWARA, 7 MD, PhD,^{1,2,6} Gen TAMIYA, PhD,^{1,2,7} Shinichi KURIYAMA, MD, PhD,^{1,2,8} 8 9 ¹ Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan 10 ² Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan 11 ³ Tohoku University Hospital, Tohoku University, Sendai, Miyagi, Japan 12 13 ⁴ Graduate School of Medicine, Teikyo University, Itabashi-ku, Tokyo, Japan ⁵ Graduate School of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, 14 15 Miyagi, Japan 16 ⁶ Suzuki Memorial Hospital, Iwanuma, Miyagi, Japan ⁷ RIKEN Center for Advanced Intelligence Project, Chuo-ku, Tokvo, Japan 17 ⁸ International Research Institute of Disaster Science, Tohoku University, Sendai, Miyagi, 18 19 Japan 20 21 **Corresponding author** 22 Mami ISHIKURO, PhD 2-1 Seirvo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan 23 Phone: +81-22-717-8104 24 Fax: +81-22-717-8106 25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 E-mail: <u>m_ishikuro@med.tohoku.ac.jp</u>
- 27
- 28 **Total word count:** 6,663 words
- 29
- 30 Short Title: Preeclampsia prediction with parental genome information
- 31
- 32

1

33 Abstract (250/250 words)

Background: Genomic information from pregnant women and their husbands may provide 34 35 effective biomarkers for preeclampsia. This study investigated how parental polygenic risk 36 scores (PRSs) for blood pressure (BP) and preeclampsia are associated with preeclampsia 37 onset and evaluated predictive performances of PRSs with clinical predictive variables. 38 Methods: In the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study, participants were genotyped using either Affymetrix Axiom Japonica Array v2 (further 39 40 divided into two cohorts-the PRS training cohort and the internal-validation cohort-at a 41 ratio of 1:2) or Japonica Array NEO (external-validation cohort). PRSs were calculated for 42 systolic BP (SBP), diastolic BP (DBP), and preeclampsia. Associations between PRSs and 43 preeclampsia, including preeclampsia superimposed on chronic hypertension, were examined 44 using logistic regression analysis; prediction models were developed using a competing-risks 45 approach with clinical predictive variables and PRSs. Results: In total, 19,836 participants were included. Hyperparameters for PRS calculation 46 47 were optimized for 3,384 participants in the training cohort. In internal- and externalvalidation cohorts, 357 of 6,768 (5.3%) and 269 of 9,684 (2.8%) participants developed 48 49 preeclampsia, respectively. Preeclampsia onset was significantly associated with maternal 50 PRSs for SBP and DBP in internal- and external-validation cohorts and with paternal PRSs 51 for SBP and DBP only in the external-validation cohort. Maternal PRSs for DBP calculated 52 using "LDpred2" most improved prediction models. Maternal PRSs for DBP provided 53 additional predictive information on clinical predictive variables. Paternal PRSs for DBP 54 improved prediction models in the internal-validation cohort. 55 Conclusions: Parental PRS, along with clinical predictive variables, is potentially useful for

56 predicting preeclampsia.

2

58 Keywords

- 59 BirThree Cohort Study, blood pressure, clamping and thresholding, competing risk, family
- 60 history, genome-wide association study, hypertensive disorders of pregnancy, LDpred2,
- 61 parametric survival model, Tohoku Medical Megabank Project
- 62

63 Non-standard Abbreviations and Acronyms

64	ACOG	American College of Obstetricians and Gynecologists
65	BMI	body mass index
66	BP	blood pressure
67	C+T	clumping and thresholding
68	СН	chronic hypertension
69	CI	confidence intervals
70	DBP	diastolic blood pressure
71	DM	diabetes mellitus
72	GWAS	genome-wide association study
73	HDP	hypertensive disorders of pregnancy
74	IVF	in vitro fertilization
75	JPA NEO	Japonica Array NEO
76	JPA v2	Japonica Array v2
77	log MoM	log_{10} transformed multiple of the median
78	MAP	mean arterial pressure
79	OR	odds ratio
80	PC	principal components
81	PE	preeclampsia
82	PRS	polygenic risk score

3

- 83 SBP systolic blood pressure
- 84 SD standard deviation
- 85 SLE systemic lupus erythematosus

4

87 Introduction

Preeclampsia (PE) is a multisystem disorder characterized by de novo hypertension and 88 proteinuria, affecting approximately 3.4% of pregnant women in the USA¹ and 2.7% in 89 Japan.² It causes approximately 45,900 maternal deaths worldwide.³ There are effective 90 interventions, such as moderate exercise,⁴ aspirin,⁵ and calcium supplementation.⁶ Thus, early 91 detection of high-risk pregnancies can lead to better outcomes⁷ for mothers and fetuses. 92 93 Therefore, developing accurate PE prediction models is critical in clinical practice. More than a hundred prediction models for PE are reported,⁸ with some using 94 genomic information from pregnant women (here, "maternal genomic information").⁹⁻¹² As 95 96 the heritability of PE was estimated to be 55% in a family study, with maternal and fetal contributions accounting for 35% and 20%, respectively,¹³ maternal genomic information is 97 expected to provide a good biomarker for PE prediction. Integrating maternal genomic 98 99 information as a polygenic risk score (PRS) can potentially improve existing predictive models; however, relevant research remains insufficient. In previous studies, 9-12 PRS for 100 101 blood pressure (BP) and PE were utilized but some important clinical predictive variables such as actual measured BP values and family history of PE were not simultaneously 102 incorporated into the prediction models. Actual measured BP values in early pregnancy is an 103 effective PE biomarker and is included in many clinical prediction models.^{8, 14} Similarly, 104 105 family medical history is a predictive variable for diseases and reflects the genetic load and shared environmental factors.^{15, 16} A recent study revealed that the PRS and family medical 106 history provide complementary information on noncommunicable diseases.¹⁷ As actual 107 108 measured BP values and family history of hypertensive disorders of pregnancy (HDP) are 109 more accessible than PRS, their combined clinical usefulness with genomic information should be explored. A previous study¹⁸ reported no improvement when PRS was incorporated 110 into a prediction model with clinical predictive variables using machine learning. However, 111

112	this study had a small number of cases (< 100) and was not externally validated.
113	Given that genomic information from pregnant women's husbands (here, "paternal
114	genomic information") is transmitted to both fetal and placental tissues, paternal genomic
115	information holds predictive potential for PE. As obtaining fetal genome is difficult,
116	combining the maternal and paternal genomes may capture a comprehensive genetic
117	predisposition to PE. However, no previous studies have employed such information in PE
118	prediction models.
119	Here, we examined the relationship between genomic information from pregnant
120	women and their husbands (here, "parental genomic information"), and PE onset. Moreover,
121	we investigated whether parental PRSs have predictive information in addition to clinical
122	models, including actual measured BP values and family history of HDP.
123	
124	Materials and Methods
125	Participants
126	The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (the
127	BirThree Cohort Study) ^{19, 20} recruited pregnant women and their families between 2013 and
128	2017. More than 50 obstetric clinics and hospitals in the Miyagi Prefecture, Japan
129	participated, registering 23,406 pregnant women and their 8,823 husbands.
130	We excluded the following pregnant women from the study: those who withdrew
131	consent, had multiple pregnancies, had stillbirth before 20 weeks of gestation, and missed the
132	diagnosis of PE or delivery date. Here, we included only the first-time participations of those
133	who had multiple participations in the TMM BirThree Cohort Study.
134	Participants were genotyped using either the Affymetrix Axiom Japonica Array v2
135	(JPA v2) or Japonica Array NEO (JPA NEO). Those with missing genotyping data were
100	excluded after a standard quality control procedure 21 Those genotyped using IPA v2 were

6

137 divided into two cohorts-the PRS training cohort and the maternal internal validation 138 cohort—at a ratio of 1:2. Those genotyped using JPA NEO were defined as the maternal external validation cohort. The participants' husbands were genotyped using the same 139 140 genotyping array platform as the participants. Cohorts with participants' husbands' genotypes 141 in the maternal internal and external validation cohorts were defined as the parental internal 142 and external validation cohorts, respectively (Figure 1). Ethical approval was obtained from the Ethics Committee of the Tohoku Medical Megabank Organization (2023-4-025), and 143 144 informed consent for research participation was obtained from all participants. 145

146 **Predictive variables**

Based on previous research on PE prediction models,²²⁻²⁶ we selected following predictive 147 148 variables: maternal age at conception, pre-pregnancy body mass index (BMI), chronic 149 hypertension (CH), systemic lupus erythematosus (SLE), type 1 and 2 diabetes mellitus 150 (DM), maternal family (mother or sisters) history of HDP, conception via in vitro fertilization 151 (IVF), parity (nulliparous, parous with or without previous HDP), gestational age at the previous delivery, the inter-birth interval, and BP at the first antenatal care during 10-13 152 153 weeks of gestation. We collected BP data at 10-13 weeks of gestation, when the majority of 154 population underwent the first or second antenatal care. Mean arterial pressure (MAP) was 155 calculated and converted to \log_{10} transformed multiple of the median (log MoM) for the 156 prediction model. Paternal age and family history of HDP were obtained for paternal 157 analyses.

158

159 Polygenic risk score

160 Genotyping and PRS calculations are described in Supplementary Methods. In brief, PRSs

161 for three phenotypes, systolic BP (SBP), diastolic BP (DBP), and PE, were calculated using

7

two methods, genome-wide clumping and thresholding (C+T) and a Bayesian approach using
 LDpred2.^{27, 28} The hyperparameters were optimized in the PRS training cohort.

164

165 **Outcome measurement**

166 PE was identified based on the American College of Obstetricians and Gynecologists

167 (ACOG) guidelines from 2002^{29} using medical records at antenatal care. PE superimposed on

168 the CH was included in the definition of PE. PE was automatically diagnosed using an

algorithm based on medical record data and validated by a physician. The details are given

170 elsewhere.²³

171

172 Model development

We applied the competing risk model,³⁰ which has been validated internally and externally in 173 Europe³¹ and yielded comparable results in the TMM BirThree Cohort Study.^{22, 23} The 174 175 competing risks model assumes that all pregnant women will develop PE during pregnancy, but only some will actually develop PE because of competing of delivery without PE. We 176 employed a parametric survival model with a Gaussian distribution.³⁰ Delivery without PE 177 was considered as censored. Missing predictive variables were imputed using k-nearest 178 neighbor imputation with k = 140 (square root of the total study population³²). To assess the 179 model discrimination, Harrell's C-statistic was calculated for whole gestational age. To assess 180 181 model calibration, the calibration slope was calculated by regressing observed survival 182 outcomes on predicted gestational age at delivery with PE in the same parametric survival models.33 183

184

185 Statistical analysis

186 Baseline characteristics and PE status were compared between cohorts. *P*-values were

8

187 calculated using the *t*-test for continuous variables and chi-square test or Fisher's exact test for categorical variables. Pearson's correlation coefficients were calculated for all 188 combinations of parental PRSs using LDpred2 in the parental internal validation cohort. 189 190 Association analyses were performed using SBP-PRS, DBP-PRS, and PE-PRS using LDpred2. In the maternal internal and external validation cohorts, the associations between 191 192 maternal PRSs and PE onset were examined using logistic regression analysis adjusted for maternal age and four genetic principal components (PC). Two models were developed, one 193 194 with PRSs as continuous values and the other as tertile values. In the parental internal and 195 external validation cohorts, associations between both maternal and paternal PRSs and PE 196 onset were examined using logistic regression analysis adjusted for parental age and four 197 genetic PCs. The results of internal and external validation cohorts were merged using 198 inverse-variance weighting for meta-analysis. Interactions between maternal and paternal 199 PRSs were also examined. As subanalyses, participants with CH were excluded from the 200 study population, and analyses were performed again. 201 The prediction model was developed in two stages: identification of a suitable PRS 202 for prediction models and development of clinical prediction models using parental PRSs. In 203 the first stage, prediction models were developed using each maternal PRS, age, and four 204 genetic PCs. Based on the C-statistics of prediction models, we selected either C+T or 205 LDpred2 as the PRS calculation algorithm, and SBP-PRS, DBP-PRS, or PE-PRS as the PRS 206 phenotype. In the second stage, we created four models: reference model, family-history 207 model, at-pregnancy-confirmation model, and in-early-pregnancy model (Supplementary Method). C-statistics and calibration slopes were calculated for each model. The 95% 208 209 confidence intervals (CI) and internal validation used the bootstrap method with 1,000

210 resamplings.

211

All analyses were conducted using R (4.1.0) unless otherwise noted. We considered

a two-tailed *P*-value <0.05 as significant.

213

214 **Results**

A total of 19,836 participants were eligible for the present study: 3,384 in the PRS training

216 cohort, 6,768 in the maternal internal validation cohort, and 9,684 in the maternal external

217 validation cohort (Figure 1). In the maternal internal and external validation cohorts, 3,673

218 (54.3%) and 2,616 (27.0%) participants, respectively, had paternal genotyping data.

219 In total, 357 of 6,768 (5.3%) participants and 269 of 9,684 (2.8%) participants

developed PE in the maternal internal and external validation cohorts, respectively (Table 1).

221 Of the 3,673 and 2,616 participants in the parental internal and external validation cohorts,

respectively, 221 (6.0%) and 23 (0.9%) participants developed PE (Supplementary Table 1).

223 Participants with PE tended to have an earlier delivery; were older; had a higher BMI; had a

history of CH, DM, and SLE; were nulliparous or parous with previous PE; had a shorter last

delivery gestational age; conceived via IVF; and had a higher BP at 10–13 weeks of

gestation, with slight variations among the maternal and parental cohorts (Tables 1 and

227 Supplementary Table 1). Notable differences in the characteristics between the internal and

external validation cohorts were observed (Supplementary Tables 2 and 3). Strong

229 correlations existed between maternal PRSs or among paternal PRSs, whereas weak

230 correlations existed between maternal and paternal PRSs (Supplementary Figure 1).

In association studies for the maternal cohorts (Table 2), maternal SBP-PRS and
DBP-PRS were significantly associated with PE onset in the meta-analysis; odds ratio (OR)

and 95% CI per 1 standard deviation (SD): 1.17 (1.08–1.27) and 1.21 (1.11–1.31),

respectively. In association studies for the parental cohorts (Supplementary Table 4), maternal

and paternal PRSs were not related to PE onset in meta-analysis. Only in parental external

236 validation cohort, maternal DBP-PRS, paternal SBP-PRS, and paternal DBP-PRS were

10

associated with PE onset; OR and 95% CI per 1 SD: 1.79 (1.14–2.81), 1.97 (1.28–3.04), and
2.04 (1.32–3.17), respectively. Similar results were observed after excluding participants with
CH. However, the results did not converge in the parental external validation cohort because
of the small number of outcomes (Supplementary Tables 5 and 6). No interaction was noted
between the maternal and paternal PRSs (data not shown).

After parameter optimization in the PRS training cohort, the predictive performances of SBP-, DBP-, and PE-PRS calculated using the two methods, C+T and LDpred2, were compared in the maternal internal and external validation cohorts (Table 3). The DBP-PRS calculated using LDpred2 improved the discrimination performance the most in both the internal (0.568 in the model with PRS vs. 0.562 in the model without PRS) and external (0.602 in the model with PRS vs. 0.555 in the model without PRS) validation.

248 Thereafter, clinical prediction models were developed with maternal and paternal DBP-PRSs calculated using LDpred2. In the maternal cohort, models including maternal PRS 249 250 demonstrated superior predictive discrimination compared to models without maternal PRS 251 in the reference and family-history models in internal validation. This was also observed in 252 all four external validation models, namely the reference, family-history, at-pregnancyconfirmation, and in-early-pregnancy models (Table 4). For example, in external validation, 253 254 the C-statistics of the at-pregnancy-confirmation model were 0.778 without PRS and 0.788 with maternal PRS, indicating the utility of maternal PRS at pregnancy confirmation. Even in 255 256 the in-early-pregnancy model, which included BP in early pregnancy, the C-statistics 257 improved slightly by including maternal PRS (0.841 without PRS vs. 0.844 with maternal PRS), suggesting the utility of maternal PRS in the prediction of early pregnancy. In the 258 parental internal validation cohort (Table 5), paternal PRS, but not maternal PRS, improved 259 260 the reference, family-history, and at-pregnancy-confirmation models. In the parental external validation cohort, maternal, but not paternal, PRS improved the reference and family-history 261

11

models, although C-statistics and calibration had a wide 95% CI and the results were not
stable. Models with both maternal and paternal PRSs did not demonstrate better
discrimination ability than those with either maternal or paternal PRS (Table 5).

265

266 Discussion

The maternal SBP- and DBP-PRSs were consistently associated with PE onset in the internal and external validation cohorts. The paternal SBP- and DBP-PRSs were associated with PE onset only in the external validation cohort. Maternal DBP-PRS calculated using LDpred2 improved prediction models the most. Maternal DBP-PRS improved both at-pregnancyconfirmation and in-early-pregnancy models, indicating the clinical utility of maternal PRS. Paternal PRS improved prediction models in the parental internal validation cohort.

273 The present study shows that maternal PRSs for BP were associated with PE onset in both internal and external validation cohorts, consistent with previous studies in the European 274 population,^{9,10} indicating cross-ethnicity generalizability. Moreover, maternal PRS improved 275 the prediction model beyond a family history of HDP. While family history provides plentiful 276 information on genetic predisposition and environment.¹⁵ the amount of information is 277 determined by family structure and relationships, as well as by disease prevalence. Owing to 278 the demographic trend toward smaller families³⁴ and the need to obtain data retrospectively 279 because of the transient nature of the condition during pregnancy, obtaining a comprehensive 280 281 family history of HDP is difficult. Less than 2% of the participants and less than 1% of 282 participants' husbands reported a family history of HDP in our cohort. Moreover, reliance only on binary categorization of family history may result in overlooking of the intricate 283 genetic predisposition. Therefore, incorporating PRSs into risk prediction models in addition 284 285 to family history is crucial for precision medicine. Maternal PRS improved at-pregnancyconfirmation model and slightly improved the in-early-pregnancy model. This indicates that 286

12

287 the maternal PRS is useful in clinical practice at pregnancy confirmation and even in early 288 pregnancy, although its predictive significance is diminished by the fact that some genetic predisposition for high BP may manifest itself as the actual measured BP values in early 289 290 pregnancy. In contrast, PE-RPS was not associated with the development of PE in this metaanalysis. The GWAS for PE³⁵ used in our study had a relatively small number of cases, and 291 292 the number of East Asian populations in the GWAS was limited (123 in the BioBank Japan, 1031 in the UK Biobank, and 1,324 in the FinnGen), which might result in failure to reflect 293 294 genetic PE predisposition.

295 Furthermore, in this study, paternal PRSs for BP were associated with PE onset in 296 the external validation cohort. The paternal genetic contribution to PE onset has been predicted in family¹³ and genetic studies.³⁶ However, as of date, the association between 297 paternal PRS and PE onset has not been investigated. Our results were inconsistent between 298 299 the internal and external validation cohorts. One possible reason for this is the biological 300 differences between the parental internal and external validation cohorts. Placental and maternal factors are involved in the development of PE.³⁷ The baseline characteristics of the 301 parental internal and external cohorts were quite different; the prevalence of CH in 302 participants with PE was much higher in the external validation cohort than in the internal 303 304 validation cohort (91.3% vs. 24.9%). This may have led to differences between the two cohorts in terms of the ratio of placental to maternal contributions, resulting in different 305 306 associations between paternal PRSs and PE. Paternal PRS improved the prediction models in 307 the parental internal validation cohort, despite no significant association in the association 308 analyses. The prediction models developed in the parental internal validation cohort did not have predictive power in the parental external validation cohort possibly, because of cohort 309 310 differences, as mentioned previously. This suggests that the contribution of paternal PRS to PE onset may differ across populations and should be considered when developing predictive 311

13

312 models.

313

314 Strengths and Limitations

Our study is the first to investigate the utility of maternal and paternal PRS for PE prediction.
We applied a well-validated prediction model; therefore, our results are close to clinical
application. Two cohorts with genomic data from different genotype array platforms and
baseline characteristics enabled us to examine the generalizability of the results.

319 Despite these strengths, our study had four limitations. First, our model did not 320 include effective biomarkers specific to PE, such as the uterine artery pulsatility index and placental growth factor,²⁵ which may have improved the performance. However, given the 321 322 widespread use of genomic information beyond perinatal diseases, prediction models using 323 PRS may be more clinically applicable than those using disease-specific biomarkers. Second, 324 there were several differences between the internal and external validation cohorts. The 325 external validation cohort included more participants with CH, which was the strongest 326 predictive variable, than the internal validation cohort, resulting in calibration slopes >1 in 327 the external validation. Moreover, in the external cohort, a family history of HDP was not 328 associated with PE, limiting the purpose of this study to confirm the predictive value of the 329 PRS in addition to a family history of HDP. Third, because there is no paternal genome-wide 330 association study (GWAS) on PE, we had no choice but to apply the maternal GWAS to the 331 fathers. Fourth, owing to the small number of parental cohorts, the effectiveness of paternal 332 PRS in predicting PE may have been overlooked. Optimization was conducted only for 333 maternal PRS, which may have resulted in an underestimation of the ability of paternal PRS 334 to predict PE.

335

336 **Perspectives**

337	Genomic information remains unchanged and can be used throughout life. This is a crucial
338	difference from other biomarkers, ²⁵ which are only reflective of temporary conditions. In
339	addition, PRS is useful for predicting diseases other than those in the perinatal period. ^{38, 39}
340	Given the unchangeability of genomic information, our study suggests that genomic
341	information should be obtained during the relatively healthy childbearing age rather than
342	during middle or old age to avoid poor outcomes in pregnant women due to inadequate
343	prediction of PE. We showed that maternal PRS can improve clinical PE prediction models
344	and suggest its application in other perinatal diseases. In addition, we showed that the utility
345	of paternal genomic information in predicting PE is inconsistent across cohorts; therefore,
346	further studies should aim at identifying populations in which paternal PRS has predictive
347	information for PE.
348	
349	Novelty and Relevance
350	What is New?
351	• Maternal and paternal genomic information improves clinical prediction models for
352	preeclampsia.
353 354	What is Relevant?Preeclampsia is a multisystem disorder characterized by de novo hypertension and
355	proteinuria, affecting approximately 3.4% of pregnant women in the USA and 2.7% in
356	Japan.
357	• Early detection of high-risk pregnancies of preeclampsia can lead to better outcomes
358	for mothers and fetuses. Therefore, developing accurate prediction models is critical
359	in clinical practice.
360	Clinical/Pathophysiological Implications
361	• This study mayidas new insights into the utility of generated companie information for
	• This study provides new insights into the utility of parental genomic information for

strategies. 363

365	Acknowledgements:	The authors wo	ould like to the	nank all t	he participan	ts who cons	sented to
366	participate in this stu	idy and all the	staff at the	Tohoku N	Aedical Meg	abank Orga	nization,
367	Tohoku University, l	wate Tohoku M	Medical Meg	abank O	rganization,	and Iwate	Medical
368	University. A full lis	t of the membe	ers of the To	hoku Me	dical Megab	ank Organi	zation is
369	available	at	https://www	.megabar	nk.tohoku.ac.	jp/english/a	230901/.

- 370 Sources of Funding: This work was supported by the Japan Agency for Medical Research
- and Development (AMED), Japan (Grant Nos. JP19gk0110039, JP17km0105001,
- 372 JP21tm0124005, and JP21tm0424601) and JSPS KAKENHI (Grant No. JP21K10438).

- Disclosures: KM is an employee of the Ministry of Education, Culture, Sports, Science and 373
- Technology, Japan. 374

19

376 References

- 1. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-
- 378 2010: age-period-cohort analysis. *BMJ*. 2013;347:f6564.
- 2. Shiozaki A, Matsuda Y, Satoh S, Saito S. Comparison of risk factors for gestational
- 380 hypertension and preeclampsia in Japanese singleton pregnancies. J Obstet Gynaecol
- 381 *Res.* 2013;39:492-499.
- 382 3. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of
- 383 maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease
- 384 Study 2015. *Lancet*. 2016;388:1775-1812.
- 385 4. Davenport MH, Ruchat SM, Poitras VJ, Garcia AJ, Gray CE, Barrowman N, Skow RJ,
- 386 Meah VL, Riske L, Sobierajski F, et al. Prenatal exercise for the prevention of
- 387 gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic

review and meta-analysis. *Br J Sports Med.* 2018;52:1367-1375.

- 389 5. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C,
- 390 Akolekar R, Cicero S, Janga D, Singh M, et al. Aspirin versus placebo in pregnancies at
- high risk for preterm preeclampsia. *N Engl J Med*. 2017;377:613-622.
- 392 6. Woo Kinshella ML, Sarr C, Sandhu A, Bone JN, Vidler M, Moore SE, Elango R,
- 393 Cormick G, Belizan JM, Hofmeyr GJ, et al. Calcium for pre-eclampsia prevention: A
- 394 systematic review and network meta-analysis to guide personalised antenatal care.
- *BJOG*. 2022;129:1833-1843.
- 396 7. Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. *N Engl J Med*.
 397 2022;386:1817-1832.
- Be Kat AC, Hirst J, Woodward M, Kennedy S, Peters SA. Prediction models for
 preeclampsia: A systematic review. *Pregnancy Hypertens*. 2019;16:48-66.
- 400 9. Kivioja A, Toivonen E, Tyrmi J, Ruotsalainen S, Ripatti S, Huhtala H, Jääskeläinen T,

n	Λ
L	υ

401		Heinonen S, Kajantie E, Kere J, et al. Increased risk of preeclampsia in women with a
402		genetic predisposition to elevated blood pressure. <i>Hypertension</i> . 2022;79:2008-2015.
403	10.	Nurkkala J, Kauko A, Laivuori H, Saarela T, Tyrmi JS, Vaura F, Cheng S, Bello NA,
404		Aittokallio J, Niiranen T. Associations of polygenic risk scores for preeclampsia and
405		blood pressure with hypertensive disorders of pregnancy. J Hypertens. 2023;41:380-
406		387.
407	11.	Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HM, Guerrero RF,
408		Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia and
409		gestational hypertension. Nat Med. 2023;29:1540-1549.
410	12.	Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S,
411		Karjalainen J, Ripatti S, Kivioja A, Laisk T, et al. Genetic risk factors associated with
412		preeclampsia and hypertensive disorders of pregnancy. JAMA Cardiol. 2023;8:674-683.
413	13.	Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors
414		account for most of familial aggregation of preeclampsia: a population-based Swedish
415		cohort study. Am J Med Genet A. 2004;130A:365-371.
416	14.	Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH. Mean arterial pressure in the
417		three trimesters of pregnancy: effects of maternal characteristics and medical history.
418		Ultrasound Obstet Gynecol. 2015;45:698-706.
419	15.	Valdez R, Yoon PW, Qureshi N, Green RF, Khoury MJ. Family history in public health
420		practice: a genomic tool for disease prevention and health promotion. Annu Rev Public
421		Health. 2010;31:69-87 1 p following 87.
422	16.	Bennett RL. The family medical history. Prim Care. 2004;31:479-495, vii-viii.
423	17.	Mars N, Lindbohm JV, della Briotta Parolo P, Widén E, Kaprio J, Palotie A, Ripatti S.
424		Systematic comparison of family history and polygenic risk across 24 common
425		diseases. Am J Hum Genet. 2022;109:2152-2162.

426	18.	Kovacheva VP, Eberha	rd BW, Cohen RY, I	Maher M, Saxena R ar	nd Gray KJ.
-----	-----	----------------------	--------------------	----------------------	-------------

- 427 Preeclampsia Prediction Using Machine Learning and Polygenic Risk Scores From
- 428 Clinical and Genetic Risk Factors in Early and Late Pregnancies. *Hypertension*.
- **429** 2024;81:264-272.
- 430 19. Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, Sakaida M,
- 431 Suzuki Y, Nakayama K, Hashizume H. The Tohoku Medical Megabank Project: design
 432 and mission. *J Epidemiol*. 2016;26:493-511.
- 433 20. Kuriyama S, Metoki H, Kikuya M, Obara T, Ishikuro M, Yamanaka C, Nagai M,
- 434 Matsubara H, Kobayashi T, Sugawara J, et al. Cohort profile: Tohoku Medical
- 435 Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort
- 436 Study): rationale, progress and perspective. *Int J Epidemiol*. 2020;49:18-19m.
- 437 21. Yamada M, Motoike IN, Kojima K, Fuse N, Hozawa A, Kuriyama S, Katsuoka F,
- 438 Tadaka S, Shirota M, Sakurai M, et al. Genetic loci for lung function in Japanese adults
- 439 with adjustment for exhaled nitric oxide levels as airway inflammation indicator.
- 440 *Commun Biol.* 2021;4:1288.
- 441 22. Ohseto H, Ishikuro M, Obara T, Murakami K, Onuma T, Noda A, Ueno F, Iwama N,
- 442 Kikuya M, Metoki H, et al. Preeclampsia prediction model using the dipstick test for
- 443 proteinuria during early gestation. *Hypertens Res Pregnancy*. 2022;10:88-96.
- 444 23. Ohseto H, Ishikuro M, Obara T, Murakami K, Onuma T, Noda A, Takahashi I,
- 445 Matsuzaki F, Ueno F, et al. Dietary calcium intake was related to the onset of pre-
- 446 eclampsia: the TMM BirThree Cohort Study. J Clin Hypertens (Greenwich).
- 447 2023;25:61-70.
- 448 24. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model
- in screening for preeclampsia by maternal characteristics and medical history. Am J
- 450 *Obstet Gynecol.* 2015;213:62.e1-62.e10.

451	25.	O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
452		Competing risks model in screening for preeclampsia by maternal factors and
453		biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214:103.e1-103.e12.
454	26.	Bartsch E, Medcalf KE, Park AL, Ray JG, High Risk of Pre-eclampsia Identification
455		Group. Clinical risk factors for pre-eclampsia determined in early pregnancy:
456		systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753.
457	27.	Choi SW, Mak TS, O'Reilly PF. Tutorial: A guide to performing polygenic risk score
458		analyses. Nat Protoc. 2020;15:2759-2772.
459	28.	Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinformatics.
460		2021;36:5424-5431.
461	29.	ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and
462		management of preeclampsia and eclampsia. Int J Gynaecol Obstet. 2002;77:67-75.
463	30.	Wright D, Wright A, Nicolaides KH. The competing risk approach for prediction of
464		preeclampsia. Am J Obstet Gynecol. 2020;223:12-23.e7.
465	31.	Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH.
466		Predictive performance of the competing risk model in screening for preeclampsia. Am
467		J Obstet Gynecol. 2019;220:199.e1-199.e13.
468	32.	Zhang Z. Introduction to machine learning: k-nearest neighbors. Ann Transl Med.
469		2016;4:218.
470	33.	Rahman MS, Ambler G, Choodari-Oskooei B, Omar RZ. Review and evaluation of
471		performance measures for survival prediction models in external validation settings.

- 472 *BMC Med Res Methodol.* 2017;17:60.
- 473 34. United Nations Department of Economic and Social Affairs Population Division.
- 474 Patterns and Trends in Household Size and Composition: Evidence from a United
- 475 *Nations Dataset 2019:ST/ESA/SER*:A/433.

- 476 35. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma
- 477 T, Yamamoto K, Akiyama M, et al. A cross-population atlas of genetic associations for
- 478 220 human phenotypes. *Nat Genet*. 2021;53:1415-1424.
- 479 36. Galaviz-Hernandez C, Arámbula-Meraz E, Medina-Bastidas D, Sosa-Macías M,
- 480 Lazalde-Ramos BP, Ortega-Chávez M, Hernandez-García L. The paternal
- 481 polymorphism rs5370 in the EDN1 gene decreases the risk of preeclampsia. *Pregnancy*
- 482 *Hypertens*. 2016;6:327-332.
- 483 37. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and
 484 clinical implications. *BMJ*. 2019;366:12381.
- 485 38. Briggs SE, Law P, East JE, Wordsworth S, Dunlop M, Houlston R, Hippisley-Cox J,
- 486 Tomlinson I. Integrating genome-wide polygenic risk scores and non-genetic risk to
- 487 predict colorectal cancer diagnosis using UK Biobank data: population based cohort
 488 study. *BMJ*. 2022;379:e071707.
- 489 39. Wedekind LE, Mahajan A, Hsueh WC, Chen P, Olaiya MT, Kobes S, Sinha M, Baier
- 490 LJ, Knowler WC, McCarthy MI, et al. The utility of a type 2 diabetes polygenic score
- 491 in addition to clinical variables for prediction of type 2 diabetes incidence in birth,
- 492 youth and adult cohorts in an Indigenous study population. *Diabetologia*. 2023;66:847-
- 493

860.

- 494
- 495
- 496

²³

	Maternal internal validation cohort					Maternal external validation cohort			
	(n = 6,768)					(<i>n</i> = 9,684)			
	DE	Not	D 1	<i>n</i> of	DE	Not	D 1	<i>n</i> of	
	PE	affected	<i>P</i> -value	missing	PE	affected	<i>P</i> -value	missing	
	<i>n</i> = 357	<i>n</i> = 6,411			<i>n</i> = 269	<i>n</i> = 9,415			
Gestational age, weeks	38.6 ± 2.1	39.2 ± 1.6	< 0.001	0	38.2 ± 2.9	39.1 ± 1.7	< 0.001	0	
Maternal age at conception, years	31.9 ± 5.5	31.5 ± 5.0	0.194	0	32.1 ± 5.2	31.4 ± 5.0	0.014	0	
Pre-pregnancy BMI, kg/m ²	23.5 ± 4.9	21.6 ± 3.4	< 0.001	113	23.3 ± 4.9	21.4 ± 3.3	< 0.001	124	
СН, %	107 (30.0)	174 (2.7)	< 0.001	0	104 (38.7)	191 (2.0)	< 0.001	0	
DM (type 1 or 2), %	8 (2.2)	17 (0.3)	< 0.001	2,162	0 (0.0)	9 (0.1)	>0.999	3,818	
SLE, %	2 (0.6)	5 (0.1)	0.049	2,162	2 (0.7)	3 (0.0)	0.007	3,818	
Maternal family history of HDP, %	13 (3.6)	135 (2.1)	0.081	2,162	3 (1.1)	158 (1.7)	0.632	3,818	
Parity			< 0.001	30			< 0.001	167	
Nullingrous 94	182 (51 0)	2,790	2,790		108 (40.1)	3,609			
Trumparous, %	162 (31.0)	(43.5)			108 (40.1)	(38.3)			

TABLE 1. Baseline characteristics in the maternal internal and external cohort, stratified by the PE status

Parous with previous PE, %	29 (8.1)	175 (2.7)			27 (10.0)	262 (2.8)		
Derous with no provious DE 0/	146 (40.0)	3,446			124 (40.8)	5,544		
Falous with no previous FE, %	140 (40.9)	(53.8)			134 (49.8)	(58.9)		
Inter-birth interval, years	3.9 ± 3.4	3.6 ± 2.6	0.267	206	3.8 ± 3.0	3.6 ± 2.6	0.514	399
Last delivery gestational age, weeks	38.5 ± 2.4	39.0 ± 1.5	< 0.001	1,257	38.4 ± 1.8	39.0 ± 1.6	< 0.001	2,020
Conception by IVF, %	30 (8.4)	301 (4.7)	0.002	62	16 (5.9)	418 (4.4)	0.303	335
MAP at 10–13 weeks of gestation, mmHg	90.0 ± 11.7	80.4 ± 9.4	< 0.001	973	91.5 ± 11.6	79.6 ± 9.3	< 0.001	1,328

PE: preeclampsia; BMI: body mass index; CH: chronic hypertension; DM: diabetes mellitus; SLE: systemic lupus erythematosus; HDP:

hypertensive disorders of pregnancy; IVF: in vitro fertilization; MAP: mean arterial pressure.

Data are shown as mean \pm standard deviation for continuous variables and n (%) for categorical variables.

P-values were calculated using the chi-square or Fisher's exact test for categorical variables and the t-test for continuous variables.

Missing values were imputed using the k-nearest neighbor imputation with k = 140 (square root of the total study population).

	Internal validation cohort External validation cohort		Meta-analysis			
	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value
PRS for SBP						
Continuous	1.05 (0.94–1.17)	0.399	1.36 (1.20–1.54)	< 0.001	1.17 (1.08–1.27)	< 0.001
Tertile 1	Reference		Reference		Reference	
Tertile 2	1.09 (0.83–1.45)	0.525	1.06 (0.78–1.44)	0.712	1.08 (0.88–1.33)	0.472
Tertile 3	1.02 (0.78–1.34)	0.867	1.74 (1.30–2.32)	< 0.001	1.31 (1.07–1.60)	0.008
PRS for DBP						
Continuous	1.09 (0.98–1.22)	0.119	1.38 (1.22–1.57)	< 0.001	1.21 (1.11–1.31)	< 0.001
Tertile 1	Reference		Reference		Reference	
Tertile 2	0.77 (0.57–1.03)	0.082	1.39 (1.02–1.88)	0.036	1.02 (0.83–1.26)	0.835
Tertile 3	1.09 (0.84–1.42)	0.498	2.20 (1.63-2.96)	< 0.001	1.48 (1.22–1.80)	< 0.001
PRS for PE						
Continuous	0.89 (0.80–1.00)	0.047	1.14 (1.01–1.28)	0.030	1.00 (0.92–1.09)	0.961
Tertile 1	Reference		Reference		Reference	

TABLE 2. Relationship between maternal PRSs and PE onset in the maternal cohorts by logistic regression analysis

Tertile 2	0.94 (0.73–1.21)	0.625	1.45 (1.07–1.95)	0.016	1.12 (0.92–1.36)	0.241
Tertile 3	0.80 (0.62–1.05)	0.111	1.21 (0.89–1.64)	0.231	0.96 (0.78–1.17)	0.677

PRS: polygenic risk score; PE: preeclampsia; OR: odds ratio; CI: confidence interval; SBP: systolic blood pressure; DBP: diastolic blood pressure.

Two models were developed, one with PRS as a continuous value and the other as tertile values.

All results were adjusted for maternal age at conception and four genetic principal components.

498

	Systolic blood pressure		Diastolic blo	od pressure Preeclampsia			
	LDpred2	C+T	LDpred2	C+T	LDpred2	C+T	No PRS
C-statistics							
Apparent	0.573	0.572	0.575	0.573	0.574	0.573	0.572
Аррасни	(0.537-0.606)	(0.537–0.604)	(0.538–0.607)	(0.538–0.604)	(0.537–0.605)	(0.538–0.604)	(0.538–0.604)
Internal	0 564	0 561	0 568	0 562	0 567	0 562	0 562
validation	0.304	0.301	0.308	0.302	0.307	0.302	0.302
External	0.591	0.558	0.602	0.563	0.532	0.540	0.555
validation	(0.550–0.629)	(0.516–0.599)	(0.564–0.639)	(0.524–0.604)	(0.489–0.573)	(0.498–0.582)	(0.515–0.597)
Calibration slope							
Apparent	1.004	1.004	1.000	1.006	1.001	1.005	1.003
	(0.554–1.383)	(0.535–1.391)	(0.564–1.376)	(0.540–1.399)	(0.556–1.376)	(0.554–1.395)	(0.535–1.406)
Internal	0.823	0.819	0.828	0.811	0.835	0.813	0.846

TABLE 3. Prediction performance with maternal PRS derived from three phenotypes using two methods

validation

External	1.105	0.884	1.184	0.921	0.554	0.748	0.861
validation	(0.599–1.537)	(0.339–1.358)	(0.702–1.610)	(0.362–1.405)	(-0.011–1.080)	(0.161–1.249)	(0.300–1.346)

PRS: polygenic risk score.

PRSs were calculated for three phenotypes, systolic blood pressure, diastolic blood pressure, and preeclampsia, using two methods, LDpred2 and

C+T.

Models without PRS included maternal age and four genetic principal components as predictive variables, and the others included additional

PRSs.

95% confidence intervals and internal validation used the bootstrap method with 1,000 resamplings.

501

TABLE 4. Performance of prediction models with maternal PRS	b, baseline characteristics,	and blood pressure in early	pregnancy in the maternal

cohorts

	No PRS	M-PRS
C-statistics		
Apparent		
Reference model	0.561 (0.533–0.590)	0.575 (0.538–0.607)
Family-history model	0.567 (0.537–0.596)	0.577 (0.539–0.609)
At-pregnancy-confirmation model	0.733 (0.700–0.766)	0.738 (0.706–0.771)
In-early-pregnancy model	0.779 (0.748–0.810)	0.781 (0.750–0.810)
Internal validation		
Reference model	0.561	0.568
Family-history model	0.566	0.570
At-pregnancy-confirmation model	0.727	0.726
In-early-pregnancy model	0.776	0.775
External validation		
Reference model	0.576 (0.543–0.609)	0.602 (0.564–0.639)

Family-history model	0.571 (0.537–0.602)	0.595 (0.558–0.632)
At-pregnancy-confirmation model	0.778 (0.742–0.813)	0.788 (0.751–0.822)
In-early-pregnancy model	0.841 (0.811–0.869)	0.844 (0.812–0.871)
Calibration slope		
Apparent		
Reference model	1.006 (0.536–1.419)	1.000 (0.564–1.376)
Family-history model	0.995 (0.536–1.407)	0.996 (0.573–1.359)
At-pregnancy-confirmation model	1.001 (0.895–1.105)	1.001 (0.897–1.108)
In-early-pregnancy model	1.002 (0.898–1.097)	1.002 (0.900-1.098)
Internal validation		
Reference model	0.995	0.828
Family-history model	0.963	0.834
At-pregnancy-confirmation model	0.951	0.939
In-early-pregnancy model	0.956	0.946
External validation		
Reference model	1.195 (0.650–1.690)	1.184 (0.702–1.610)

Family-history model	0.857 (0.399–1.285)	0.909 (0.487–1.297)
At-pregnancy-confirmation model	1.210 (1.093–1.320)	1.203 (1.084–1.314)
In-early-pregnancy model	1.168 (1.060–1.278)	1.147 (1.036–1.256)

PRS: polygenic risk score; CI: confidence interval.

"No PRS" indicates models without PRS and "M-PRS" indicates models with maternal PRS for diastolic blood pressure.

Reference models included maternal age.

Family-history models included maternal family history of hypertensive disorders of pregnancy and maternal age.

At-pregnancy-confirmation models included variables available at pregnancy confirmation: maternal age, pre-pregnancy body mass index,

chronic hypertension, systemic lupus erythematosus, diabetes mellites, maternal family history of hypertensive disorders of pregnancy,

conception via in vitro fertilization, parity, gestational age at the previous delivery, and the inter-birth interval.

At-early-pregnancy models added blood pressure in early pregnancy to at-pregnancy-confirmation models.

Models with M-PRS also included maternal four genetic principal components.

95% confidence intervals and internal validation used bootstrap method with 1,000 resamplings.

	No PRS	M-PRS	P-PRS	M-PRS and P-PRS
C-statistics				
Apparent				
Deferrer ee medel	0.573	0.588	0.609	0.609
Kelerence model	(0.538–0.610)	(0.545–0.627)	(0.566–0.650)	(0.564–0.650)
	0.577	0.588	0.612	0.613
Family-history model	(0.540–0.614)	(0.543–0.628)	(0.568–0.655)	(0.568–0.654)
At-pregnancy-confirmation	0.718	0.725	0.728	0.731
model	(0.674–0.756)	(0.685–0.762)	(0.685–0.768)	(0.688–0.770)
	0.770	0.770	0.776	0.776
In-early-pregnancy model	(0.733–0.803)	(0.732–0.802)	(0.738–0.808)	(0.739–0.809)
Internal validation				
Reference model	0.574	0.574	0.600	0.597
Family-history model	0.578	0.577	0.602	0.599
At-pregnancy-confirmation	0.706	0.705	0.714	0.712

TABLE 5. Prediction performance with parental PRS, baseline characteristics, and blood pressure in early pregnancy in the parental cohorts

model

In-ea	rly-pregnancy model	0.761	0.757	0.761	0.759
External v	alidation				
D (0.609	0.657	0.525	0.560
Refe	rence model	(0.486–0.738)	(0.525–0.776)	(0.372–0.686)	(0.420–0.713)
F '	1 1	0.600	0.647	0.518	0.551
Fami	ly-history model	(0.480–0.729)	(0.515–0.765)	(0.365–0.679)	(0.414–0.706)
At-pr	regnancy-confirmation	0.981	0.980	0.981	0.981
mode	el	(0.957–0.993)	(0.953–0.993)	(0.964–0.991)	(0.958–0.992)
Ŧ		0.985	0.982	0.982	0.979
In-ea	rly-pregnancy model	(0.970–0.993)	(0.964–0.991)	(0.968–0.991)	(0.962–0.989)
Calibration slo	ope				
Apparent					
		0.989	0.989	0.988	0.992
Refer	rence model	(0.510–1.414)	(0.594–1.350)	(0.635–1.346)	(0.685–1.301)
Fami	ly-history model	0.994	0.992	0.986	0.995

	(0.518–1.411)	(0.596–1.374)	(0.637–1.360)	(0.680–1.302)
At-pregnancy-confirmation	0.999	1.000	1.001	0.998
model	(0.845–1.151)	(0.847–1.151)	(0.848–1.152)	(0.847–1.149)
In carly programaty model	1.001	1.001	1.000	0.999
m-early-pregnancy model	(0.867–1.135)	(0.870–1.136)	(0.870–1.137)	(0.871–1.135)
Internal validation				
Reference model	1.012	0.822	0.837	0.765
Family-history model	0.958	0.822	0.796	0.739
At-pregnancy-confirmation	0.011	0.800	0.871	0.852
model	0.911	0.890	0.071	0.832
In-early-pregnancy model	0.920	0.900	0.884	0.866
External validation				
Pafaranca model	1.236	1.080	0.545	0.498
Reference model	(-0.033–2.217)	(-0.151–2.002)	(-0.760–1.567)	(-0.633–1.451)
Family-history model	0.958	0.847	0.408	0.381
ranny-mstory moder	(-0.215–1.829)	(-0.259–1.692)	(-0.816–1.344)	(-0.684–1.256)

At-pregnancy-confirmation	1.796	1.755	1.731	1.691
model	(1.544–2.198)	(1.500–2.182)	(1.457–2.133)	(1.427–2.116)
In-early pregnancy model	1.550	1.479	1.505	1.435
m-carry-pregnancy moder	(1.313–1.947)	(1.242–1.877)	(1.256–1.922)	(1.196–1.855)

PRS: polygenic risk score; CI: confidence interval.

"No PRS," "M-PRS," "P-PRS," and "M-PRS and P-PRS" indicate models without PRS, models with maternal PRS for diastolic blood pressure, models with paternal PRS for diastolic blood pressure, and models with both maternal and paternal PRS for diastolic blood pressure, respectively.

Reference models included maternal age.

Family-history models included maternal family history of hypertensive disorders of pregnancy and maternal age.

At-pregnancy-confirmation models included variables available at pregnancy confirmation: maternal age, pre-pregnancy body mass index,

chronic hypertension, systemic lupus erythematosus, diabetes mellitus, maternal family history of hypertensive disorders of pregnancy,

conception by in vitro fertilization, parity, gestational age at the previous delivery, and the inter-birth interval.

At-early-pregnancy models added blood pressure in early pregnancy to at-pregnancy-confirmation models.

Paternal age at conception was included in all the models with paternal PRS and paternal family history of HDP was included in all the models with paternal PRS except for reference models.

Models with M-PRS and P-PRS also included maternal and paternal four genetic principal components, respectively.

95% confidence intervals and internal validation used the bootstrap method with 1,000 resamplings.

506 **Figures with Figure Legends**



507

508 FIGURE 1. TMM BirThree Cohort Study flow for three study cohorts

509 After excluding ineligible participants, the cohort was divided into three cohorts, namely PRS

510 training, maternal internal validation, and maternal external validation. The cohorts with

511 participants' husbands' genotypes in the maternal internal and external validation cohorts

512 were the parental internal and external validation cohorts, respectively.

513 TMM BirThree Cohort Study: The Tohoku Medical Megabank Project Birth and Three-

514 Generation Cohort Study.

515 JPA v2: Affymetrix Axiom Japonica Array v2; JPA NEO: Affymetrix Axiom Japonica Array

516 NEO.